Clinical Trial Search

Primary: Ocular Redness as Measured by the Investigator Using the Ora Calibra™ Ocular Hyperemia Scale — 1.82; 1.71; 0.58; 1.40 units on a scale

Primary: Ocular Redness — 0.46; 0.53; 0.40; 0.49 score on a scale

Primary: Mean Change From Baseline in Overall Diastolic Ocular Perfusion Pressure at Week 6 — 2.6; 0.8 mmHg (millimeters of mercury)

Primary: Number of Participants With Photographic Haze Reduced to Grade 0 or Down 2 Steps Documented With Fundus Photography — 3; 1; 1 Participants

Primary: Change From Baseline in Intraocular Pressure (IOP) at Week 8 — -4.68; -3.68; -4.56; -3.62 mm Hg

Primary: Changes From Baseline (Day 1 Pre-dose) in Ocular Tolerability Using a Visual Analogue Scale (VAS) — -22.8; -30.1; -20.9; -20.9 mm — p=0.3474

Primary: Irritation Response Evaluation According to Erythema Scoring Scale During Induction Phase - All Enrolled Subjects — 2182; 2 Test site

Primary: Change From Baseline in Overall Conjunctival Hyperemia Score — -0.056; -0.330; -0.352 score on a scale — p=0.218

Primary: Change in Palpebral Fissure Height — 1.1; -0.4 mm

Primary: Duration of Episode (DOE) Was Measured in Hours (Using the Science 37 Platform), of a Single Treated Herpes Labialis (HL) Lesion — 66.5; 73.6 Hours — p=0.716

Primary: Ocular Itching Change From Baseline to Day 11 — -1.1; -0.45 units on a scale

Primary: Change From Baseline in Ocular Itching at 14 Days — 2.17; 1.82 units on a scale

Primary: Inflammation Change From Baseline to Day 6 — -1.2; -0.19 score on a scale

Primary: Mean Conjunctival Hyperemia at Week 12 — 0.42; 0.46; 0.44 Score on a scale

Primary: Tear Evaporation Rate — 39.0; 44.8; 30.6; 26.7 Watt/meter^2